News

In June 2007, GlaxoSmithKline (GSK) announced the launch of a randomized, double-blind, and placebo-controlled Phase III clinical trial in lung cancer to evaluate the MAGE-A3 Antigen-Specific Cancer Immunotherapeutic

The company has granted a 30-day option to the underwriters to purchase up to an additional 15% of the offering to cover over-allotments. The net proceeds to the

Jerini has received technical clearance of its electronic common technical document from the agency, which ensures that the documentation meets the agency’s technical standards. Priority review designation, which

Valsartan is indicated for the treatment of hypertension alone or in combination with other anti-hypertensive agents. Valsartan is also indicated for the treatment of heart failure. Jim Meehan,

Under the terms of this agreement, Asuragen will have the right to develop, manufacture and market products for the diagnosis, stratification and monitoring of patients with Acute Myeloid

The results showed that Concerta achieved a significantly superior reduction in adult ADHD investigator symptom rating scale (AISRS) total score compared to placebo (p=0.012) (mean change was -10.6

In vitro data showed significant (p

Pathway’s SensiTrop technology is designed to enable physicians to identify the HIV co-receptor tropism status of a patient infected with HIV, the virus that causes AIDS. Pathway’s technology

Xanafide (amonafide malate) is an ATP-independent topoisomerase II inhibitor that the company is developing for the treatment of secondary acute myeloid leukemia (AML) and related disorders. Xanafide is